Clinical trial
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
NCT02407210 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- Not reported
- Enrollment
- 304 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.